click tracking

About Us

Recent News

July, 2017: PepVax, Inc., an early stage biotechnology company developing an immunotherapy treatment for triple-negative breast cancer (TNBC), today announced several new milestones and upcoming events that demonstrate the company's continued growth...Read more...

June, 2015: Paper published by PepVax describing the Epitope specificity and protein signaling interactions driving epidemic occurrences of Ebola disease. Ebolavirus has as main hosts, humans and nonhuman primates where its pathogenic effects result to serious hemorrhagic fever with lethal...
Read more...

TEDCO Press Release: Maryland Entrepreneur List Success Story
Read more...

Washington Business Journal: Can Indiegogo fund biotech? PepVax bets on it
Read more...